At BioSima, we believe that exosome technology has the power to revolutionize the therapeutic approach to inumerous pathologies. Our products are developed based on solid scientific research and are designed to provide consistent results.
Explore our catalog and discover accessible and innovative therapies, designed to meet specific needs from exosome administration for tumor remission to treatments for neurodegenerative diseases.
BioSima is committed to providing high-quality products that drive clinical excellence
Discovery
Pré-clinical
Phase I
Phase II
Based on results obtained in the pre-clinical stages of research carried out by the founders of BioSima and on the international literature, BioSima currently presents a pipeline of biotechnological products associated with exosome therapies, namely the acellular exosomal concentrate (ConExo), which constitutes an exosomic compound in natura (naive) derived from autologous adipogenic mesenchymal stem cell cultures currently undergoing phase I/II clinical trial in Brazil.
The therapeutic potential of exosomes is based on the presence of proteins and other specific chemokines carried by these nanovesicles, which play an important role in the intercellular communication by paracrine signaling mechanisms (between different cells). They contribute in the uptake/recruitment of local cells and induce their proliferation, differentiation and protein synthesis.
The addition of exosomal concentrate (ConExo) to bone substitutes commonly used in Orthopedic and Maxillary/Dental surgeries might improve the healing performance and local tissue response, in terms of the speed of maturation/incorporation of these biomaterials by the basal human skeleton bone, as well as to accelerate the deposition of local mineral content at grafted areas, aiming a greater density/maturation of the newly formed calcified tissue.
diseases
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of ß-amyloid peptide and tau phosphorylation in the brain. The mechanism of propagation of these cytotoxic agents among neurons is still unknown. Recent research has revealed that exosomes derived from cells may play an important role in this transmission process. Additionally, various genetic materials and molecules also participate in intercellular communication through exosome secretion. This suggests new possibilities for early diagnosis and biological treatment of AD, based on exosome intervention.
BioSima has been researching the use of therapeutic exosomes targeted to the central nervous system (CNS), via intranasal delivery, against targets of neurodegenerative diseases such as Alzheimer’s.
Type 1 diabetes mellitus (T1DM), characterized as a multifactorial disease dependent on the complex interaction between predisposing genetic factors, immune response, and environmental influences, is a chronic autoimmune disease that results in the destruction of pancreatic β cells and, consequently, in the loss of insulin production and secretion.
Based on its studies, BioSima believes in the therapeutic potential of acellular therapies; e.g. the use of exosomes to mitigate apoptosis and endoplasmic reticulum stress of pancreatic β cells. Exosomes have a dual function in mediating insulin resistance/sensitivity, potentially containing miRNAs that regulate various molecular pathways such as AMPK, PI3K/Akt, and β-catenin, affecting the progression of T1DM.
Unlike other intercellular transporters such as liposomes and polymeric nanoparticles, exosomes have the unique potential to serve as an endogenous machinery that can be utilized for drug delivery and distribution. They possess properties such as protection of encapsulated proteins or drugs due to their small size, which aids exosomes in avoiding phagocytosis. Exosome cargoes exhibit high biocompatibility, are non-immunogenic, can travel long distances, be targeted, and overcome a variety of physical barriers due to their properties.
Recent research conducted by BioSima shows that exosomes internalize drugs such as chemotherapeutics used in the adjuvant therapy of early-stage breast cancer, for example. The delivery of effector molecules into tumor cells can not only act on tumor remission but also avoid cytotoxicity in adjacent organs.
CNPJ: 47.635.783/0001-43
contato@biosima.bio